Superoxide dismutase activity as a predictor of adverse outcomes in patients with nonischemic dilated cardiomyopathy

Ewa Romuk · Wojciech Jacheń · Ewa Kozielska-Nowalany · Ewa Birkner · Aleksandra Zemła-Woszek · Celina Wojciechowska

Received: 26 January 2019 / Revised: 28 March 2019 / Accepted: 29 March 2019 / Published online: 1 May 2019

Abstract

Oxidative stress contributes to progression of heart failure (HF). The present study analyzed the efficacy of the activities of superoxide dismutase (SOD) and its isoenzymes (CuZnSOD and MnSOD) as prognostic factors in dilated cardiomyopathy. The usefulness of activities of total SOD, MnSOD, and CuZnSOD was assessed, taking into account clinical, echocardiographic, and laboratory parameters as risk predictors of long-term clinical outcomes (death, heart transplant, combined end point) in 109 patients with nonischemic dilated cardiomyopathy (NIDCM) in this study with a 5-year follow-up. Regression analysis showed that total serum SOD activity was a predictor of worse long-term clinical outcome even after adjustment for NT-proBNP, hemoglobin, sodium, creatinine clearance, left ventricular ejection fraction (LVEF), BMI, and NYHA class (LVEF: HR 1.059, 95% CI 1.007–1.114, \(P = 0.026\); BMI: HR 1.073, 95% CI 1.021–1.126, \(P = 0.005\); NYHA: HR 1.073, 95% CI 1.022–1.126, \(P = 0.005\)). MnSOD and CuZnSOD activities were also predictors of worse long-term clinical outcome even after adjustment for laboratory parameters and BMI or NYHA class; however, after adjustment for LVEF, a borderline statistical significance was achieved (LVEF: HR 1.054, 95% CI 0.993–1.119, \(P = 0.081\) [MnSOD]; HR 1.092, 95% CI 0.989–1.297, \(P = 0.082\) [CuZnSOD]). Increased activities of total serum SOD and its isoenzymes in NIDCM patients correspond with a poor prognosis and may have prognostic value in the prediction of long-term clinical outcomes. In conclusion, the present study shows that serum SOD activity may be a useful predictor of adverse outcome in HF.

Keywords Dilated cardiomyopathy · Heart failure · Oxidative stress · Superoxide dismutase

Introduction

Nonischemic dilated cardiomyopathy (NIDCM) is a common disease of the heart muscle (Jeffries and Towbin 2010). It is a frequent cause of heart failure (HF), which leads to heart transplant (HT) at a relatively young age (Felker et al. 2000). Advancement of knowledge in the pathophysiology of HF, efforts to facilitate early diagnosis, and use of effective pharmacological treatments and device therapies have contributed greatly to improving patients’ survival in the last few years.
mechanisms of cardiac remodeling (Nonaka-Sarukawa et al. 2003). Increased myocardial oxidative stress (OS), which is observed in animal models, plays a pivotal role in the pathogenesis of cardiac injury and the progression of HF (Nojiri et al. 2006; Chamiot et al. 2011).

Several factors and mechanisms, including xanthine oxidase (XO), NAD(P)H oxidases, cytochrome P450, auto-oxidation of catecholamines, and uncoupling of nitric oxide synthase (NOS) cause an increased production of reactive oxygen species (ROS) in a failing heart (Giordano 2005; Nordberg and Arner 2001).

The primary defense system against oxidative stress consists of antioxidant enzymes, including superoxide dismutase (SOD), catalase, and glutathione peroxidase, heat shock protein enzymes-heme oxygenases (HOs) which have essential antioxidant capacity for many tissues including cardiovascular system cells (Haines and Tosaki 2018) and nonenzymatic components, including glutathione, metallothionein, α-tocopherol, and ascorbate. SOD catalyzes dismutation of $\cdot{O}_2^-$ to hydrogen peroxide ($H_2O_2$). $H_2O_2$ is a relatively less toxic molecule and under physiological conditions is eliminated by catalase or glutathione peroxidase. However, $H_2O_2$ and $O_2^-$ may generate highly reactive and toxic hydroxyl radicals ($OH^{-}$). A manganese-containing isoenzyme, manganese superoxide dismutase (MnSOD), located within the mitochondrial matrix, is responsible for prompt conversion of mitochondrial $O_2^-$ to $H_2O_2$, which is less reactive, and better crosses cell membranes. Copper/zinc-containing SOD (CuZnSOD) is a cytosolic enzyme that catalyzes the same reaction. This enzyme plays a predominant role in superoxide dismutation, although this reaction also occurs nonenzymatically. Our research identified both forms of SOD: the mitochondrial MnSOD and the cytosolic CuZnSOD, along with the extracellular SOD (EC-SOD), which is similar to the cytosolic CuZnSOD (Petersen et al. 2003). MnSOD is of particular interest because of its strategic location in the mitochondria, a major site of $O_2$ production under hypoxic conditions (Tsan et al. 1998). Biomarkers including oxidative stress markers may provide valuable new insight into the pathophysiology and prognosis of HF. There is growing evidence that oxidative stress may contribute to disease progression in dilated cardiomyopathy. Hence, the purpose of this study was to critically evaluate superoxide dismutase activity as a predictor of adverse outcomes in patients suffering from heart failure due to dilated cardiomyopathy.

Methods

Patients

We recruited 109 consecutive patients aged 49.4 ± 17.5 years with NIDCM, diagnosed according to the World Health Organization criteria (Richardson et al. 1996). All patients were considered to be potential heart transplant recipients and admitted to the Second Department of Cardiology, School of Medicine, with the Division of Dentistry, Medical University of Silesia, Poland, between 2006 and 2011 due to a follow-up procedure. Depending on the results of noninvasive assessment, an invasive assessment (right heart catheterization) was performed in most patients. Patients were clinically stable and their therapy had not been changed for at least 1 month before the enrollment. Ischemic etiology was previously excluded by coronary angiography. All patients in this study were nonsmokers and had not taken any antioxidant supplements and/or vitamins for at least 3 days before the examination. Exclusion criteria included valvular heart disease, significant renal insufficiency, inflammatory or infectious disorders, and other diseases which, by themselves, could have reduced survival. All patients received optimal conventional heart failure therapy, including angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), beta-blockers, mineralocorticoid receptor antagonists (MRA), digitalis, and diuretics.

According to the clinical status, the patients were followed on an outpatient basis and examined at least every 6 months, for a period of 5 years. For all patients, endpoint data were collated. The exact date of death was obtained from the patient’s medical history, information from his/her relatives, and, in other cases, from the national identification number database. Written informed consent was obtained from all enrolled patients. The study protocol was approved by the Bioethics Committee of Medical University of Silesia.

Clinical assessment

Clinical evaluation included a medical examination incorporating assessment of New York Heart Association (NYHA) class, electrocardiogram, and echocardiography. Echocardiography images were acquired in standard views following the recommendations of the American Society of Echocardiography.

Blood sample collection

Blood samples of all subjects were collected on the day of clinical assessment (which included electrocardiogram and echocardiography at the start of the study). The samples were collected in the morning before breakfast, after 12 h of overnight fasting. All blood samples (5 ml) were taken from the basilic vein into two kinds of tubes: ethylendiamintetraacetic acid (1.6 mg/ml EDTA-K3) tubes for hemoglobin determination and clot activator containing tubes. The blood samples were centrifuged (10 min, 1500 g, 4 °C), and the serum was immediately separated. Routine laboratory determinations were made (creatinine, hemoglobin, sodium, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) from
Biochemical methods

The serum superoxide dismutase (SOD, EC 1.15.1.1) activity was determined by the Oyanagui method (Oyanagui 1984). In this method, XO catalyzes the oxidation of hypoxanthine to xanthine and generates superoxide in the presence of oxygen. Increasing activity of SOD in the samples causes a decrease in superoxide concentration and a reduction of the product color (naphthyl ethylenediamine and sulfanilic acid).

Activities of SOD isoenzymes, MnSOD and CuZnSOD, were measured with the use of potassium cyanide (KCN) as inhibitor of the CuZnSOD isoenzyme. CuZnSOD activity was taken as the difference between the total SOD activity and the MnSOD activity. The activity of SOD was calculated against a blank probe (containing bi-distilled water). Enzyme activity was expressed as nitrite units (NU) per milliliter serum. One NU exhibits 50% inhibition of formation of nitrite ion under the method's condition. The inter- and intra-assay coefficients of variations (CV) were 2.8% and 5.4%, respectively.

Malondialdehyde was measured according to the method described by Ohkawa using the reaction with thiobarbituric acid (Ohkawa et al. 1979). NT-proBNP was measured by electrochemiluminescence (Cobas 6000e501, Roche Diagnostics, Mannheim, Germany). Additionally, we also examined hemoglobin, sodium, and creatinine concentrations using routine techniques (Cobas Integra 800, Roche Diagnostics). Glomerular filtration rate (eGFR), an indicator of renal function, was estimated from serum creatinine using the Cockcroft-Gault Equation.

Endpoints of the study

The endpoints of the study were as follows: heart transplant (HT), all-cause mortality, and combined endpoint (all-cause mortality or heart transplant).

Statistical analysis

For the purpose of analysis, the study group was divided into four groups according to the outcome: group A, patients who survived without endpoints; group B, patients who underwent a heart transplant; group C, patients who died; and group D, patients who achieved a combined endpoint. Categorical data were presented as numbers and percentages. Because of the small sample size, continuous data were expressed as median and interquartile range (25–75%). The significance of baseline differences between groups was determined using the chi-square test with Yates correction for categorical data or the unpaired Mann-Whitney U test for continuous data, as appropriate. The Spearman rank correlation method was used as a nonparametric measure of association for correlations between SOD activities and clinical and biochemical variables. Cumulative survival curves were constructed as time to the endpoint by Kaplan-Meier methods, and the differences between patients, with activities of SOD and its isoenzymes below and above the median, were tested for significance by the log-rank test.

As a first step in the development of risk models, univariate analyses using Cox regression were performed in the study population to determine the relationships between known risk factors and endpoints. The clinical, echocardiographic, and laboratory variables, which differed significantly under comparative statistics, were included in a univariate Cox analysis. Multivariate Cox regression analyses were subsequently performed, with risk factors associated with the combined endpoint in the univariate analysis; only variables with a value of P ≤ 0.1 at univariate analysis were included in the multivariate model. Three different models including laboratory parameters and separately, total SOD, MnSOD, and CuZnSOD were fit for use as the combined endpoint. These models were adjusted subsequently for LVEF, body mass index (BMI), and NYHA class. We decided to use LVEF (not the left ventricular end-diastolic volume [LVEDV]), for multivariate analysis. LVEF and LVEDV are derivatives and in the two-factor analysis, a stronger predictive value was demonstrated by LVEF (LVEF: hazard ratio [HR] 0.934, 95% confidence interval [CI] 0.887–0.983; LVEDV: HR 1.028, 95% CI 0.988–1.069). The results of the Cox analysis were reported as relative risks with corresponding 95% CI. The results were considered statistically significant if P < 0.05. Statistical analysis was performed with STATISTICA, version 10.0 (StatSoft, Inc., Tulsa, OK, USA).

Results

Clinical and laboratory characteristics

A total of 109 patients (16 females; mean age 49.4 [37.6–57.2] years) with NIDCM were examined with a 5-year-long follow-up; of these, 40 (36.7%) patients achieved the endpoint, 15 (13.8%) patients underwent heart transplant, and 25 (22.9%) patients died. All patients received optimal medical treatment according to current guidelines (Swedberg et al. 2005). Majority of them received β-blockers (93.6%), ACE-I (92.7%), ARB (37.6%), and MRA (91.7%). Some patients were treated with digitalis (63.3%), loop diuretics (61.5%), and thiazide diuretics (17.4%). In the presented group, 34 (31.2%) patients were maintained on ACE-I and ARB combination therapy under strict potassium and creatinine control.
Thirty-three percent of the patients had an implantable cardioverter-defibrillator. Patients from groups C and D received loop diuretics more frequently. Otherwise, pharmacological and electro-therapies were not different. The demographic, clinical, and echocardiographic baseline characteristics for all groups and subgroups are presented in Table 1, and laboratory parameters are shown in Table 2.

The percentage of comorbidities was low, and it did not differ between groups. More patients from groups B and D were in the advanced NYHA functional class (III and IV) as compared to group A. Echocardiography showed a typical enlargement of the left ventricle and markedly depressed LVEF (25.0 [20.0–30.0%]). LVEF values in patients who achieved endpoints (groups B, C, and D) were significantly lower as compared to group A. Groups B, C, and D had significantly higher NT-proBNP concentration and lower creatinine clearance compared to group A. The hemoglobin and sodium concentrations were lower in groups B and D.

**Comparison of activities of total SOD and its isoenzymes in patients with dilated cardiomyopathy group according to the prognosis**

Total SOD activity was statistically significantly higher in the HT and combined endpoint groups as compared to patients who survived without endpoint ($p < 0.01$). MnSOD activity was statistically significantly higher in patients who died or achieved the combined endpoint ($p < 0.05$, $p < 0.01$), whereas CuZnSOD activity was statistically significantly higher only in HT patients as compared to patients who survived without endpoint during the 5-year follow-up ($p < 0.05$).

### Table 1  Demographic, clinical, and selected echocardiography date in subgroups separated according to prognosis

|                | A Survivors $n = 69$ | B HT $n = 15$ | C Death $n = 25$ | D HT or death $n = 40$ |
|----------------|----------------------|--------------|------------------|------------------------|
| Sex (female), n (%) | 10 (14.5)           | 2 (13.3)     | 4 (16)           | 6 (15.0)               |
| Age (years)      | 49.39 (37.56–56.51) | 49.06 (42.99–54.76) | 50.30 (36.45–87.90) | 49.44 (38.58–57.90) |
| BMI (kg/m²)      | 28.37 (25.78–31.35) | 25.53AA (21.81–26.65) | 27.68 (23.77–29.70) | 25.83AA (22.64–29.05) |
| NYHA class I–II/III–IV (%) | 51/18 (73.9/26.1) | 4/11AAA (26.6/73.4) | 15/10 (60.0/40.0) | 19/21AAA (47.5/52.5) |
| Disease duration (years) | 3.21 (1.38–6.15) | 5.59A (4.05–9.36) | 3.19 (0.76–5.51) | 4.36 (1.71–6.15) |
| ICD, n (%)       | 23 (20.9)            | 7 (46.7)     | 3 (12.0)         | 10 (25.0)              |
| HA, n (%)        | 20 (29.0)            | 2 (13.3)     | 7 (28.0)         | 9 (22.5)               |
| DM t. 2, n (%)   | 8 (11.6)             | 1 (6.7)      | 2 (8.0)          | 3 (7.5)                |
| Sinus rhythm, n (%) | 55 (79.7)         | 12 (80.0)    | 21 (84.0)        | 33 (82.5)              |
| Atrial fibrillation, n (%) | 14 (20.3)      | 3 (20.0)     | 4 (16.0)         | 7 (17.5)               |
| LVEF (%)         | 25.00 (20.00–30.00) | 20.00^AAA (15.00–21.00) | 20.00^A (15.00–26.00) | 20.00^AAA (15.00–25.00) |
| LVEDV (ml)       | 185.0 (153.0–240.0) | 219.0 (181.5–265.0) | 238.0^A (170.0–297.0) | 229.0^A (178.0–270.0) |
| LVEDD (mm)       | 68.00 (62.00–74.00) | 73.00^A (68.00–78.50) | 69.00 (62.00–80.00) | 71.00 (65.00–80.00) |

HT heart transplant, BMI body mass index, NYHA class New York Heart Association functional class, ICD implantable cardioverter-defibrillator, HA arterial hypertension, DM t. 2 diabetes t. 2, LVEF left ventricle ejection fraction, LVEDV left ventricle end-diastolic volume, LVEDD left ventricle end-diastolic diameter

Statistic significance: $^A p < 0.05$, $^{AA} p < 0.01$, $^{AAA} p < 0.001$ when compared to A group
Table 2  Activity of serum biomarkers in subgroups separated according to prognosis

|                  | A Survivors | B HT | C Death | D HT or death |
|------------------|------------|------|---------|---------------|
| NTproBNP [pg/ml] | 605.0      | 239.5 | 142.0   | 1606.0        |
| [ml/min]         | 100.6–149.8| 74.15–112.2| 92.31–138.6| 83.87–134.7  |
| Sodium [mmol/l]  | 138.0      | 135.0 | 138.0   | 135.5         |
| CuZnSOD [NU/ml]  | 10.48      | 17.49 | 13.00   | 17.70         |
| MnSOD [g/dl]     | 7.25       | 10.96 | 12.05   | 11.23         |
| NTproBNP [pg/ml] | 3.37–12.89 | 9.138–12.12 | 5.10–15.30 | 5.77–15.06 |
| CuZnSOD [g/dl]   | 2.37–6.53  | 4.52–8.63 | 3.71–7.33 | 4.20–7.58   |
| MDA [μmol/l]     | 4.51       | 4.37  | 4.22    | 4.26         |
| Hemoglobin [g/dl]| 136.0–154.0| 126.0–142.0 | 130.0–153.0| 128.0–151.0 |

HT heart transplant, NT-proBNP N-terminal pro-B-type natriuretic peptide, CC creatinine clearance, SOD superoxide dismutase, MnSOD manganese superoxide dismutase, CuZnSOD copper-zinc superoxide dismutase, MDA malondialdehyde

Statistic significance: *p < 0.05, **p < 0.01, ***p < 0.001 when compared to A group, ^p < 0.05 when compared to B group

Correlation between SOD isoenzymes and clinical and biochemical parameters

We observed significant correlation between SOD isoenzymes and severity of HF (as defined by LVEF, NYHA class, and NT-proBNP) in all the groups. Furthermore, the total SOD and MnSOD activities correlated negatively with BMI and creatinine clearance (Table 3). Surprisingly, there was no correlation between SOD and MDA.

Follow-up and predictors of unfavorable outcomes

To evaluate the efficacy of SOD activity as a prognostic factor for adverse clinical outcome in NIDCM, we subdivided the patients according to their SOD activity into two groups: patients with SOD activity below and those with SOD activity above the median SOD activity. Kaplan-Meier curves based on SOD, MnSOD, and CuZnSOD activities for all-cause mortality, heart transplant, and combined endpoint groups are shown in Figs. 1, 2, and 3, respectively.

Log-rank analysis for all endpoints revealed that a serum MnSOD activity > 9.13 NU/ml was a predictor of poor prognosis in patients with NIDCM (Figs. 1B, 2B, and 3B).

Stratification based on the median SOD activity revealed that patients with higher SOD (total SOD activity > 15.48 NU/ml) underwent HT or achieved the combined endpoint more often. CuZnSOD was useful only in the prediction of HT in patients with NIDCM.

Univariate analysis identified only higher concentration of NT-proBNP and increased LVEDV as predictors of death (Fig. 4). In univariate analysis, poor prognostic factors for HT in this study group were lower levels of the following parameters: BMI, LVEF, hemoglobin, sodium, and higher levels of the following indices: NYHA class, NT-proBNP concentrations, creatinine clearance, SOD, and CuZnSOD activities (Fig. 5). Similarly, the above factors and higher MnSOD activity and LVEDV were associated with combined endpoint occurrence (Fig. 6). Multivariate analysis was performed for the combined endpoint only. This was dictated by a limited number of completed endpoints.

In multivariate analysis, activities of total SOD and its isoenzymes, MnSOD and CuZnSOD, remained independent prognostic factors of the combined endpoint even after adjustment for all significant biochemical predictors, BMI, and NYHA class.

The inclusion of LVEF in the multivariate model did not abolish the prognostic significance of activity of total SOD. In this regression model (taking into account the LVEF value), activities of CuZnSOD and MnSOD, and the concentration of NT-proBNP did not reach statistical significance (Figs. 7, 8, and 9).
Fig. 1 Kaplan–Meier death-free survival in 5-year long follow-up depending on total SOD (c), MnSOD (b), and CuZnSOD (a) activity in NIDCM patients

Fig. 2 Kaplan–Meier heart transplantation-free survival in 5-year long follow-up depending on total SOD (c), MnSOD (b), and CuZnSOD (a) activity in NIDCM patients

Fig. 3 Kaplan–Meier death- or heart transplantation-free survival in 5-year long follow-up depending on total SOD (c), MnSOD (b), and CuZnSOD (a) activity in NIDCM patients
### Risk factors of death under univariable Cox regression model in 5-year follow-up

| Risk Factor                          | HR     | 95% CI       | p     |
|-------------------------------------|--------|--------------|-------|
| Disease duration [year]              | 0.95   | 0.867-       | 0.40  |
| BMI [kg/m²]                         | 0.93   | 0.853-       | 0.15  |
| LVEF [%]                            | 0.75   | 0.569-       | 0.05  |
| LVEDD [10mm]                        | 1.08   | 0.730-       | 0.69  |
| LVEDV [10mm]                        | 1.06   | 1.017-       | 0.00  |
| NYHA [by one class]                 | 1.25   | 0.700-       | 0.44  |
| Hemoglobin [g/dl]                   | 0.98   | 0.956-       | 0.22  |
| MDA [µmol/l]                        | 0.88   | 0.701-       | 0.29  |
| CuZn-SOD [NU/ml]                    | 1.06   | 0.935-       | 0.35  |
| Mn-SOD [NU/ml]                      | 1.05   | 0.996-       | 0.06  |
| SOD [NU/ml]                         | 1.05   | 0.996-       | 0.07  |
| sodium [mmol/l]                     | 0.94   | 0.858-       | 0.25  |
| Creatinine clearance [10 ml/min]    | 0.94   | 0.854-       | 0.27  |
| NTproBNP [100 pg/ml]                | 1.03   | 1.006-       | 0.01  |

Fig. 4 Cox proportional-hazards regression for 5-year mortality rate in relation to biochemical, demographical, and clinical factors

### Risk factors of HT under univariable Cox regression analysis in 5-years follow-up

| Risk Factor                          | HR     | 95% CI       | p     |
|-------------------------------------|--------|--------------|-------|
| Disease duration [year]              | 1.00   | 0.971-       | 0.73  |
| BMI [1 kg/m²]                       | 0.84   | 0.748-       | 0.01  |
| LVEF [%]                            | 0.52   | 0.347-       | 0.00  |
| LVEDD [10mm]                        | 1.60   | 0.912-       | 0.10  |
| LVEDV [10mm]                        | 1.03   | 0.973-       | 0.28  |
| NYHA [by one class]                 | 3.80   | 1.990-       | 0.00  |
| Hemoglobin [g/dl]                   | 0.94   | 0.911-       | 0.00  |
| MDA [µmol/l]                        | 0.99   | 0.773-       | 0.94  |
| CuZn-SOD [NU/ml]                    | 1.22   | 1.070-       | 0.00  |
| Mn-SOD [NU/ml]                      | 1.06   | 0.978-       | 0.15  |
| SOD [NU/ml]                         | 1.08   | 1.013-       | 0.02  |
| sodium [mmol/l]                     | 0.81   | 0.741-       | 0.00  |
| Creatinine clearance [10 ml/min]    | 0.79   | 0.666-       | 0.01  |
| NTproBNP [100 pg/ml]                | 1.06   | 1.035-       | 0.00  |

Fig. 5 Cox proportional-hazards regression for HT rate in relation to biochemical, demographical, and clinical factors
Risk factors of death or HT under univariable Cox regression model in 5-year follow-up

| Risk Factor                        | HR    | 95% CI       | p    |
|-----------------------------------|-------|--------------|------|
| Disease duration [year]           | 0.992 | 0.954-       | 0.670|
| BMI [1 kg/m2]                     | 0.900 | 0.838-       | 0.008|
| LVEF [%]                          | 0.669 | 0.530-       | 0.001|
| LVEDD [10 mm]                     | 1.240 | 0.852-       | 0.200|
| LVEDV [10 mm]                     | 1.052 | 1.016-       | 0.005|
| NYHA [by one class]               | 1.994 | 1.321-       | 0.001|
| Hemoglobin [g/dl]                 | 0.969 | 0.948-       | 0.006|
| Creatinine clearance [10 ml/min]  | 0.926 | 0.782-       | 0.376|
| Sodium [mmol/l]                   | 1.129 | 1.028-       | 0.011|
| CuZn-SOD [NU/ml]                  | 1.060 | 1.009-       | 0.021|
| Mn-SOD [NU/ml]                    | 1.063 | 1.019-       | 0.004|
| SOD [NU/ml]                       | 0.884 | 0.824-       | 0.001|
| MDA [umol/l]                      | 0.897 | 0.820-       | 0.018|
| NT-proBNP [100 pg/ml]             | 1.050 | 1.030-       | 0.001|

Fig. 6 Cox proportional-hazards regression for 5-year mortality or HT rate in relation to biochemical, demographical, and clinical factors

CuZnSOD activity, biochemical markers activity and LVEF, BMI, NYHA class, as risk factors of death or HT in 5-years follow-up in Multivariable Cox regression model

| Risk Factor                        | HR    | 95% CI       | P   |
|-----------------------------------|-------|--------------|-----|
| CuZn-SOD [NU/ml]                  | 1.092 | 0.989-       | 0.082|
| Hemoglobin [g/dl]                 | 0.963 | 0.940-       | 0.003|
| Sodium [mmol/l]                   | 0.929 | 0.863-       | 0.052|
| Creatinine clearance [10 ml/min]  | 0.959 | 0.879-       | 0.344|
| NT-proBNP [100 pg/ml]             | 1.02  | 0.994-       | 0.131|
| LVEF [%]                          | 0.763 | 0.583-       | 0.048|
| CuZn-SOD [NU/ml]                  | 1.132 | 1.027-       | 0.013|
| Hemoglobin [g/dl]                 | 0.967 | 0.944-       | 0.009|
| Sodium [mmol/l]                   | 0.927 | 0.860-       | 0.049|
| Creatinine clearance [10 ml/min]  | 0.969 | 0.881-       | 0.514|
| NT-proBNP [100 pg/ml]             | 1.026 | 1.002-       | 0.032|
| BMI [1 kg/m2]                     | 0.968 | 0.894-       | 0.418|
| CuZn-SOD [NU/ml]                  | 1.131 | 1.026-       | 0.013|
| Hemoglobin [g/dl]                 | 0.967 | 0.944-       | 0.007|
| Sodium [mmol/l]                   | 0.934 | 0.866-       | 0.081|
| Creatinine clearance [10 ml/min]  | 0.959 | 0.875-       | 0.367|
| NT-proBNP [100 pg/ml]             | 1.026 | 1.002-       | 0.035|
| NYHA [by one class]               | 1.164 | 0.715-       | 0.542|

Fig. 7 Multivariable Cox proportional-hazards regression for CuZnSOD activity, LVEF, BMI, NYHA class, and biochemical parameters as risk factors of death or HT in 5-year follow-up
Discussion

This study is the first to assess the impact of SOD activity on the long-term prognosis of patients with nonischemic dilated cardiomyopathy. Increased activities of total SOD and its isoenzymes predicted death and/or the necessity of a heart transplant during the 5-year follow-up period. Oxidative stress and free radicals are described as the main causes of nonischemic cardiomyopathy in experimental and clinical studies. For example, enhanced generation of ROS seems to be crucial in explaining the toxicity of ethanol in alcoholic cardiomyopathy (Eleawa et al. 2015). The contribution of oxidative stress is also well established in diabetic cardiomyopathy (Steiner and Lang 2017) and endemic cardiomyopathy in Keshan disease (Pei et al. 2013) or Chagas disease (Machado et al. 2013). The heart is particularly susceptible to oxidative damage, as it possesses lower levels of free radical scavengers such as CuZnSOD, catalase, and glutathione peroxidase, as compared to the liver (Chen et al. 1994). A profound impact on mitochondrial superoxide dismutase (MnSOD) has been shown in anthracycline-induced cardiomyopathy. Systemic antracycline treatment markedly downregulates the expression of MnSOD both at the level of mRNA and protein and decreases its enzymatic activity for up to 3 weeks. (Li et al. 2000). Though the abnormalities in some cardiomyopathies have been well identified, comprehensive understanding of underlying mechanisms of the myocardial remodeling process resulting in the progression of heart failure is needed. Hence, we decided to assess the usefulness of SOD in a group of patients with nonischemic dilated cardiomyopathy. The study group consisted of clinically stable patients. The proportion of patients with additional illnesses such as diabetes or hypertension was low (no complications of hypertension and diabetes were noted). Patients were young and had significantly reduced LVEF. Though endomyocardial biopsy is a well-known, sensitive, and reliable detector of oxidative stress in cardiac tissue, its invasive nature (Pei et al. 2013) significantly limits its routine use in clinical practice. Thus, we analyzed SOD activity not in heart tissue but from blood, so such factors as peripheral congestion and hypoxic condition may influence the results. However, careful patient selection ensured that we could evaluate redox parameters in HF regardless of the impact of the endothelial processes on redox balance occurring in atherosclerosis or advanced arterial hypertension. Previous studies indicate that serum SOD activity and MDA are higher in patients with NIDCM; only isoenzyme MnSOD is related to severity of HF (Wojciechowska et al.)
Similar results showing an inverse correlation of SOD activity with the cardiac index were documented by Jacheć et al. (1998). Association between SOD and glutathione reductase (GR) and severity of LV dysfunction (higher SOD and GR associated with lower LVEF, not at rest but after cardiopulmonary exercise testing) in NIDCM were observed by Simeunovic et al. (2015).

We have observed an association between the severity of LV dysfunction and SOD and GR, i.e., higher SOD and GR were associated with lower LVEF; this was observed after cardiopulmonary exercise testing in NIDCM. Keith et al. (1998) found no correlations between lipid peroxidation, MDA, and ejection fraction or LV function or dimensions (as determined by echocardiography). However, these parameters were positively correlated with the functional class of HF. Thus, we assessed the long-term prognostic and predictive value of serum SOD activity in NIDCM, together with known prognostic parameters, such as BMI, NYHA class, and LVEF. SOD had a long-term prognostic-predictive value even after adjustment for previously established prognostic factors, such as NT-proBNP, sodium and hemoglobin concentrations, creatinine clearance, LVEF, NYHA class, or BMI. The predictive efficacy of MnSOD and CuZnSOD for the combined endpoint was independent of laboratory parameters, NYHA class, and BMI. The clinical value of serum biomarkers in prognostic stratification lies in their ability to identify patients with an unfavorable prognosis more accurately, thus facilitating intensification of treatment in this subset of patients. The impact of superoxide dismutase-1 genetic variation on all-cause mortality was evaluated in a prospective cohort study by Otaki et al. (2016). Haplotype analysis revealed that some haplotypes increased, whereas others decreased the likelihood of death due to cardiovascular diseases. However, protein expression and activity of SOD1 were not measured. Only one previous study has established the prognostic role of serum SOD in cardiovascular disease (Parenica et al. 2016). SOD was useful as a predictor of 1-year all-cause mortality and/or hospitalization due to acute HF in patients after ST-elevation myocardial infarction. In the above study, patients had more frequent comorbidities and only mild postinfarct dysfunction of the left ventricle. These conditions and atherosclerotic coronary arterial lesions may affect the degree of

![Fig. 9 Multivariable Cox proportional-hazards regression for total SOD activity, LVEF, BMI, NYHA class, and biochemical parameters as risk factors of death or HT in 5-year follow-up](image-url)
Superoxide dismutase activity as a predictor of adverse outcomes in patients with nonischemic dilated... 671

disturbances in the redox balance parameters in this group of patients. However, SOD was an independently powerful prognostic factor in addition to the GRACE score. SOD also demonstrated a significant ability to predict endpoints in 2-year and 3-year follow-ups (Parenica et al. 2016). The association between serum oxidative stress markers and functional class (Wojciechowska et al. 2014; Keith et al. 1998) and the results after effort (Simeunovic et al. 2015) may support the concept that redox markers are related not only to cardiac contractility and cardiac output but also to impairment of peripheral blood flow, hypoxia, or skeletal muscle function. Surprisingly, multivariate analysis in our study abrogated the prognostic value of NYHA functional class of HF. Experimental studies have demonstrated the biological importance of SOD. In mice lacking the following mitochondrial SOD mutant, severe effects, such as inactivation of key respiratory chain and tricarboxylic acid cycle enzymes, inhibition of HMG-CoA lyase, and accumulation of oxidative DNA damage were seen (Meelov et al. 1999).

In the context of HF, most free radicals are thought to emanate from inefficient mitochondrial metabolism and/or impaired antioxidant defense (Seddon et al. 2007). MnSOD is the only SOD isoform that is essential for the survival of aerobic organisms (Carlizzo and Touati 1986; Lebovitz et al. 1996). Located in the mitochondria, MnSOD makes up > 70% of the SOD activity in the heart and > 90% of the activity in cardiac myocytes. The remaining activity of SOD is due to CuZnSOD, which is located in the cytosol (Sawyer et al. 2002). Our results demonstrate a key prognostic role of MnSOD. Log-rank analysis demonstrated that high serum MnSOD activity was a significant predictor of death, HT, or combined endpoint. Similar to Dieterich et al. (2000), we conclude that the increase in antioxidant enzyme expression is evidence of an adaptive response to the increased substrate concentration in mild oxidative stress. In an early animal study, Gupta and Singal (1989) found increased antioxidant activity consistent with the notion that oxidative stress is associated with increase in antioxidant enzyme activity. In a study by Sam et al. (2006), only CuZnSOD activity was increased in HF. Despite increase in the general expression of MnSOD, the activity of this enzyme was decreased. Taking into consideration different biochemical markers, the NT-proBNP is a new marker, which is very strongly associated with adverse outcome in patients with HF. Brain natriuretic peptide is commonly used as a diagnostic marker for HF (McDonagh et al. 2004). A previous study reports that BNP is also a predictor of all-cause and cardiovascular mortality in the general population (Parenica et al. 2016). It is worth emphasizing that carriers of superoxide dismutase-1 genetic variation associated with increased cardiovascular mortality have elevated BNP levels (Otaki et al. 2016).

Surprisingly, in our study, the predictive significance of NT-proBNP was attenuated when LVEF was included in the multivariate model. Another marker of poor prognosis in HF is low hemoglobin concentration. Under hypoxic conditions, as in heart failure, hemoglobin can contribute to production of ROS because heme releases superoxide during desaturation (Tang and Katz 2006). In patients with dilated cardiomyopathy, lower hemoglobin concentration was a useful predictor of heart transplant and combined endpoint. The association between anemia and SOD activity shows inconsistent results. Jansson et al. (1985) observed increased formation of SOD in iron-deficient rats during increased oxidative stress. Cellerino et al. (1976) reported enzyme deficiency in severe iron-deficiency anemia. We did not observe any difference in the MDA concentration between groups of patients with adverse outcomes and those who survived. We did not show that MDA from lipid peroxidation can predict mortality. Inverse correlations between the concentration of MDA and mixed venous blood oxygenation and also with total antioxidant capacity were previously observed in patients with dilated cardiomyopathy (Wojciechowska et al. 2014). This perhaps suggests that existing antioxidant defense mechanisms in stable patients are sufficient to inactivate the production of ROS. In summary, the present study demonstrates that the activities of SOD and its iso-enzymes are useful predictors of adverse outcome in patients with reduced ejection fraction heart failure due to dilated cardiomyopathy. Total SOD, MnSOD, and CuZnSOD offer a moderate improvement in risk stratification when used in combination with conventional markers and improve the assessment of prognosis beyond established clinical risk scores. However, our results need further validation and confirmation in future cohort studies. The next logical step is to obtain a nomogram by measuring representatives of distinct classes of antioxidant and oxidant factors. Furthermore, antioxidant activity has a therapeutic potential, which could reduce morbidity and mortality in patients with dilated cardiomyopathy.

**Study limitations** We do, however, acknowledge that our study has certain limitations. First, the study group was relatively small. However, the group was homogenous, of non-ischemic etiology, and patients with exacerbation of HF were not included in the study. Second, when there are a small number of endpoints, especially a combined endpoint in relation to variables in a multivariate analysis, further observation is necessary; this was not available in our study. Third, we analyzed the concentrations of biomarkers only at recruitment. They were not re-evaluated during follow-up. Finally, during follow-up, therapy was modified according to the clinical status. Thus, treatment effect during follow-up cannot be ruled out.
Funding statement The study was supported by research funding from Silesian Medical University (grant No KNW-1-116/p/1/0).

Data availability statement All of the data used to support the findings of this study are included within the article.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All subjects provided their informed consent for inclusion before they participated in the study. The study protocol was approved by the Ethics Committee of Silesian Medical University.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Bergamini C, Cicoira M, Rossi A, Vassanelli C (2009) Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 11:444–452

Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148–2159

Carlfoz A, Touati D (1986) Isolation of superoxide dismutase mutants in Escherichia coli: is superoxide dismutase necessary for aerobic life? EMBO J 5:623–630

Cellerino R, Guidi G, Perona G (1976) Plasma iron and erythrocytic glutathione peroxidase activity. A possible mechanism for oxidative haemolysis in iron deficiency anemia. Scand J Haematol 17:111–116

Charniot JC, Sutton A, Bonnefont-Rousselot D, Cosson C, Khani-Bittar R, Giral P, Charnaux N, Albertini JP (2011) Manganese superoxide dismutase dimorphism relationship with severity and prognosis in cardiacogenic shock due to dilated cardiomyopathy. Free Radic Res 45(4):379–388

Chen Y, Saati JT, Kang YJ (1994) Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic Biol Med 17:529–536

Dieterich S, Bielzik U, Beulich K, Hasenfuss G, Prestle J (2000) Gene expression of antioxidative enzymes in the human heart: increased expression of catalase in the end-stage failing heart. Circulation 101:33–39

Eleawa SM, Alkhateeb M, Ghosh S, Al-Hashem F, Shatoor AS, Alhejaila A, Khalil MA (2015) Coenzyme Q10 protects against acute consequences of experimental myocardial infarction in rats. Int J Physiol Pathophysiol Pharmacol 7(1):1–13

Ellidag H, Eren E, Yilmaz N, Cekin Y (2014) Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure. Redox Rep 19(3):118–123

Felker GM, Thompson RE, Hare JM, Hruban RH, Cleemsten DE, Howard DL, Baughman KL, Kasper EK (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 34(15):1077–1084

Giordano FJ (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115:500–508

Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O'Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK (2003) Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309(9):896–908

Gupta M, Singal PK (1989) Higher antioxidative capacity during a chronic stable heart hypertrophy. Circ Res 64:398–406

Haines D, Tosaki A (2018) Role of Heme Oxygenases in cardiovascular syndromes and co-morbidities. Curr Pharm Des 24(20):2322–2325

Jacheć W, Polonski L, Kusińierz B, Tarnowski R, Wodecki J, Tendera M, Tomaszik A (1998) Superoxide dismutase isoenzymes activity changes in the plasma of heart failure patients. Med Sci Monit 4(4):646–650

Jansson LT, Perkio MV, Willis WT, Retino CJ, Dallman PR (1985) Red cell superoxide dismutase is increased in iron deficiency anemia. Acta Haematol 74:218–221

Jefferies JL, Towbin JA (2010) Dilated cardiomyopathy. Lancet 375:752–762

Keith M, Gerannayegane A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhooy KN (1998) Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31(6):1352–1356

Lainscak M, von Haepling S, Ankler SD (2009) Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 132:303–311

Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, Huang S, Matzuk MM (1996) Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 93:9782–9787

Li T, Danelisen I, Bello-Klein AK, Singal P (2000) Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 46:523–530

Machado FS, Tanowitz HB, Ribeiro AL (2013) Pathogenesis of chagas cardiomyopathy:role of inflammation and oxidative stress. J Am Heart Assoc 2(5):e000539. https://doi.org/10.1161/JAHA.113.000539

McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ (2004) NT-proBNP and the diagnosis of heart failure: a pooled analysis of Tyree European epidemiological studies. Eur J Heart Fail 6:269–273

Meelov S, Coskun P, Patel M, Tuinstra R, Cottrell B, Jun AS, Zastawny TH, Dizdaroglu M, Goodman SI, Huang TT, Mziorko H, Epstein CJ, Wallace DC (1999) Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc Natl Acad Sci U S A 96:123

Nojiri H, Shimizu T, Funakoshi M, Yamauchi O, Zhou H, Kawakami S, Ohata Y, Sami M, Tachibana T, Ishikawa H, Kurosawa H, Kahn RC, Otsu K, Shirasawa T (2006) Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 281:33801–33808

Nonaka-Sarukawa M, Yamamoto K, Akoi UH, Takano H, Katsuki T, Ikeda U, Shimada K (2003) Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart 89:871–874

Nordberg J, Amer ES (2001) Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31:1287–1312

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351–358

Otaki Y, Watanabe T, Nishiya S (2016) The impact of superoxide Dismutase-1 genetic variation on cardiovascular and all-cause mortality in a prospective cohort study: the Yamagata (Takahata) study. PLoS One 11(10):e0164732
Oyanagui Y (1984) Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 142(2):290–296

Parenica J, Kala P, Goldbergova Pavkova M, Tomandl J, Spinar J, Littnerova S, Jarkovsky J, Mebazaa A, Tomandlova M, Dastych M, Gottwaldová J, Gayat E (2016) Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients — multiple biomarkers prospective cohort study. Int J Cardiol 211:96–104

Pei J, Fu W, Yang L, Zhang Z, Liu Y et al (2013) Oxidative stress is involved in the pathogenesis of Keshan disease (an endemic dilated cardiomyopathy) in China. Oxidative Med Cell Longev 2013:1–5. https://doi.org/10.1155/2013/474203

Petersen S, Oury TD, Valnickova Z, Thøgersen IB, Højrup P, Crapo JD, Enghild JJ (2003) The dual nature of human extracellular superoxide dismutase: one sequence and two structures. Proc Natl Acad Sci U S A 100(24):13875–13880

Richardson P, McKenna RW, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/international society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93(5):841–842

Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabae a A, Bristow MR, Colucci WS, Sawyer DB (2006) Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail 11(6):473–480

Sawyer DB, Siwik AD, Xiao L (2002) Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34:379–388

Seddon M, Looi YH, Shah AM (2007) Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93:903–907

Simeunovic D, Seferovic PM, Ristic AD, Nikolic D, Risimic D, Seferovic J, Maksimovic R, Nedeljkovic I, Karan R, Bajcetic M (2015) Evaluation of oxidative stress markers and catecholamine changes in patients with dilated cardiomyopathy before and after cardiopulmonary exercise testing. Hell J Cardiol 56(5):394–401

Steiner JL, Lang CH (2017) Etiology of alcoholic cardiomyopathy: mitochondria, oxidative stress and apoptosis. Int J Biochem Cell Biol 89:125–135

Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, Lopez-Sendon JL, Nieminen MS, Piérard L, Remme WJ (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 26(11):1115–1140. https://doi.org/10.1093/eurheartj/ehi204

Tang YD, Katz SD (2006) Anemia in chronic heart failure. Prevalence, etiology, clinical correlates, and treatment options. Circulation. 113:2454–2461

Tsan MF, White JE, Caska B, Tsan MF, White JE, Caska B, Epstein CJ, Lee CY (1998) Susceptibility of heterozygous MnSOD gene-knockout mice to oxygen toxicity. Am J Respir Cell Mol Biol 19:114–120

Wojciechowska C, Romuk E, Tomasz A, Skrzep-Poloczek B, Nowalany-Kozielska E, Birkner E, Jaceh W (2014) Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy. Mediat Inflamm article ID 147040, pp. 10 2014:1–10

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.